Equities research analysts at HC Wainwright raised their Q1 2025 earnings per share estimates for Sage Therapeutics in a ...

Sage Therapeutics SAGE announced that its board ... In the past year, the stock has plunged 72% compared with the industry’s decline of 12.4%. Earlier this month, Biogen made an acquisition ...

Scotiabank analyst George Farmer maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $12.00.

Sage Therapeutics stock gained after it announced that its board of directors has rejected the unsolicited, non-binding proposal offer from biotech giant Biogen to acquire the remaining shares of ...

Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of ...

Sage Therapeutics has a unique approach to targeting ... This, I believe, adds upside optionality to the stock. Zurzuvae is also a relatively unique IP for PPD, as it has a simple 14-day regime ...

The firm owned 18,246 shares of the biopharmaceutical company’s stock after selling 21,172 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Sage Therapeutics were ...